| Integrative genomics identifies LMO1 as a neuroblastoma oncogene. | neuroblastoma, |
| LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. | colorectal, |
| LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. | lung, |
| LMO1 is an important oncogene that promotes neuroblastoma initiation, progression, and widespread metastatic dissemination. | neuroblastoma, |
| Developmentally regulated and tissue specific expression of mRNAs encoding the two alternative forms of the LIM domain oncogene rhombotin: evidence for thymus expression. | None |
| An unusual structure of a putative T cell oncogene which allows production of similar proteins from distinct mRNAs. | None |
| Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia. | None |
| A C-to-T single nucleotide transition occurs as a somatic mutation in noncoding sequences 4 kb upstream of the transcriptional start site of the LMO1 oncogene in primary samples from patients with T-cell acute lymphoblastic leukaemia. This conforms to an APOBEC-like cytidine deaminase mutational signature and a new MYB binding site driving high levels of LMO1 expression. | None |
| Functional diversity of LIM proteins: amino-terminal activation domains in the oncogenic proteins RBTN1 and RBTN2. | None |